How tumor DNA methylation may explain survival differences between Black and White women with high‑grade serous ovarian cancer
Methylomic basis of survival disparities among Black and White women with high-grade serous ovarian cancer
Researchers are looking for tumor DNA methylation patterns that might be linked to poorer survival in Black and White women with high‑grade serous ovarian cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-11249218 on NIH RePORTER |
What this research studies
From your perspective, the team will use tumor samples and medical records from existing observational studies to compare DNA methylation in tumors from Black and White women with high‑grade serous ovarian cancer. Lab tests on tumor DNA and statistical analyses will be used to find methylation patterns that track with survival after diagnosis. The researchers will control for treatment and disease features so differences are not just due to care. Findings could point to biological changes tied to social or lifestyle factors that affect outcomes.
Who could benefit from this research
Good fit: Ideal candidates are women diagnosed with high‑grade serous ovarian cancer who have available tumor tissue and clinical follow‑up data, with emphasis on enrolling both Black and White patients.
Not a fit: People without high‑grade serous ovarian cancer, those lacking tumor tissue or follow‑up data, and men are unlikely to directly benefit from this project.
Why it matters
Potential benefit: If successful, this work could reveal tumor DNA markers that help explain survival gaps and guide more personalized prognosis or future targeted approaches for patients, especially Black women.
How similar studies have performed: Previous studies have linked DNA methylation to cancer outcomes but few have focused on racial survival differences in high‑grade serous ovarian cancer, making this a partly novel approach.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Peres, Lauren Cole — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Peres, Lauren Cole
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.